EMA emergency task force backs intradermal use of Imvanex/Jynneos monkeypox vaccine 

[Image courtesy of Pixabay]

EMA’s Emergency Task Force (ETF) has given national authorities in the EU permission to use the Imvanex vaccine as an intradermal injection while supplies of the vaccine remain limited. In a statement, the ETF described the decision as a “temporary measure.”

The FDA recently reached a similar decision but authorized the intradermal use of the Imvanex vaccine from Bavarian Nordic A/S (OMX:BAVA, OTC:BVNRY) in adults with an elevated risk of contracting monkeypox. 

The Imvanex vaccine is known as Jynneos in the U.S. 

While the EMA has only authorized subcutaneous injection of the vaccine, the ETF acknowledged that the intradermal use of the vaccine supports dose sparing, allowing a fraction of the vaccine to be administered than conventionally. 

Supplies of the vaccine remain limited throughout the world. 

Increased risk of side effects for intradermal Imvanex? <…
Read more
  • 0